Modified release dosage forms of skeletal muscle relaxants

Details Modified release dosage forms of skeletal muscle relaxants Modified release dosage forms of skeletal muscle relaxants

2008-09-24

2010-11-09

Wax, Robert A (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

C424S401000

Reexamination Certificate

active

07829121

ABSTRACT:
A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.

REFERENCES:
patent: 3155590 (1964-11-01), Miller et al.
patent: 3341416 (1967-09-01), Anderson et al.
patent: 3488418 (1970-01-01), Holliday et al.
patent: 3882246 (1975-05-01), Share
patent: 4292298 (1981-09-01), Davis
patent: 4590062 (1986-05-01), Jang
patent: 4713248 (1987-12-01), Kjornaes et al.
patent: 4728513 (1988-03-01), Ventouras
patent: 4743248 (1988-05-01), Bartoo et al.
patent: 4780319 (1988-10-01), Zentner et al.
patent: 4780463 (1988-10-01), Sunshine et al.
patent: 4789549 (1988-12-01), Khan et al.
patent: 4795644 (1989-01-01), Zentner
patent: 4814183 (1989-03-01), Zentner
patent: 4839177 (1989-06-01), Colombo et al.
patent: 4851228 (1989-07-01), Zentner et al.
patent: 4851229 (1989-07-01), Magruder et al.
patent: 4882167 (1989-11-01), Jang
patent: 4919938 (1990-04-01), Lovegrove et al.
patent: 4968507 (1990-11-01), Zentner et al.
patent: 4996047 (1991-02-01), Kelleher et al.
patent: 5008114 (1991-04-01), Lovrecich
patent: 5102668 (1992-04-01), Eichel et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5133974 (1992-07-01), Paradissis et al.
patent: 5260069 (1993-11-01), Chen
patent: 5275824 (1994-01-01), Carli et al.
patent: 5350584 (1994-09-01), McClelland et al.
patent: 5366738 (1994-11-01), Rork et al.
patent: 5401512 (1995-03-01), Rhodes et al.
patent: 5407686 (1995-04-01), Patel et al.
patent: 5422122 (1995-06-01), Powell
patent: 5582838 (1996-12-01), Rork et al.
patent: 5607671 (1997-03-01), Heino
patent: 5874418 (1999-02-01), Stella et al.
patent: 5882682 (1999-03-01), Rork et al.
patent: 5952451 (1999-09-01), Zhao
patent: 6004582 (1999-12-01), Faour et al.
patent: 6020000 (2000-02-01), Wong et al.
patent: 6191162 (2001-02-01), Byrd
patent: 6344215 (2002-02-01), Bettman et al.
patent: 6358944 (2002-03-01), Lederman et al.
patent: 6451345 (2002-09-01), Percel et al.
patent: 6500454 (2002-12-01), Percel et al.
patent: 6599529 (2003-07-01), Skinhøj et al.
patent: 6627223 (2003-09-01), Percel et al.
patent: 6663888 (2003-12-01), Percel et al.
patent: 6673367 (2004-01-01), Goldenheim et al.
patent: 7387793 (2008-06-01), Venkatesh et al.
patent: 2003/0099711 (2003-05-01), Meadows et al.
patent: 2003/0215496 (2003-11-01), Patel et al.
patent: 2004/0126427 (2004-07-01), Venkatesh et al.
patent: 2004/0166160 (2004-08-01), Subramanian et al.
patent: 2004/0197407 (2004-10-01), Subramanian et al.
patent: 2005/0013860 (2005-01-01), Venkatesh et al.
patent: 2005/0106247 (2005-05-01), Venkatesh et al.
patent: 2008/0124398 (2008-05-01), Venkatesh et al.
patent: 2008/0124399 (2008-05-01), Venkatesh et al.
patent: 2008/0279937 (2008-11-01), Venkatesh et al.
patent: 2009/0017127 (2009-01-01), Venkatesh et al.
patent: 0177000 (1986-04-01), None
patent: 0518263 (1992-12-01), None
patent: 10-1999-0039518 (2001-04-01), None
patent: WO 81/02671 (1981-10-01), None
patent: WO 85/03437 (1985-08-01), None
patent: WO 98/06439 (1998-02-01), None
patent: WO 98/18610 (1998-05-01), None
patent: WO 98/53802 (1998-12-01), None
patent: WO 99/12524 (1999-03-01), None
patent: WO 99/18937 (1999-04-01), None
patent: WO 99/30671 (1999-06-01), None
patent: WO 01/15668 (2001-03-01), None
patent: WO 03/020242 (2003-03-01), None
Rowe et al., “Ethylcellulose,” Handbook of Pharmaceutical Excipients, 5th ed., London: Pharmaceutical Press (2006), pp. 278-279.
Rekhi and Jambhekar, “Ethylcellulose—A Polymer Review,” Drug Development and Industrial Pharmacy 21:61-77(1995).
Excerpt from U.S. Pharmacopeia XXIV (1999), pp. xxvii-xxxvi (p. xxvii cited in Section I(A)(1) of C4).
Detailed Factual and Legal Basis for Paragraph IV Certification Regarding United States Patent No. 7,387,793 (included in generic pharmaceutical company's Notice Letter dated Oct. 28, 2008).
Complaint for Patent Infringement inEurand, Inc., Cephalon, Inc., and Anesta AGv.Mylan Pharmaceuticals, Inc., Mylan, Inc., Barr Pharmaceuticals, Inc. and Barr Laboratories, Inc., Civil Action No. 1:08-cv-00889-SLR, filed with the United States District Court for the District of Delaware on Nov. 25, 2008.
Complaint for Patent Infringement inEurand, Inc., Cephalon, Inc., and Anesta AGv.Mylan Pharmaceuticals, Inc. and Mylan, Inc., Civil Action No. 1:08-cv-00210-IMK, filed with the United States District Court for the Northern District of West Virginia on Nov. 26, 2008.
Copending U.S. Appl. No. 12/026,887 (divisional of U.S. Appl. No. 10/713,929), filed Feb. 6, 2008.
Notice of Allowance in Copending U.S. Appl. No. 12/026,887 (divisional of U.S. Appl. No. 10/713,929), filed Feb. 6, 2008.
Copending U.S. Appl. No. 12/026,882 (continuation of U.S. Appl. No. 10/713,929), filed Feb. 6, 2008.
Copending U.S. Appl. No. 12/236,723 (continuation of U.S. Appl. No. 10/713,929) filed Sep. 24, 2008.
Complaint for Patent Infringement inEurand, Inc., Cephalon, Inc., and Anesta AGv.Impax Laboratories, Inc., Civil Action No. 1:09-cv-00018-SLR, filed with the United States District Court for the District of Delaware on Jan. 7, 2009.
Answer and Counterclaim of Impax Laboratories, Inc. inEurand, Inc., Cephalon, Inc., and Anesta AGv.Impax Laboratories, Inc., Civil Action No. 1:09-cv-00018-SLR, filed with the United States District Court for the District of Delaware on Jan. 26, 2009.
Eurand, Inc. and Anesta AG's Answers to Impax Laboratories, Inc.'s Counterclaims,Eurand, Inc., Cephalon, Inc., and Anesta AGv. Impax Laboratories, Inc., Civil Action No. 1:09-cv-00018-SLR, filed with the United States District Court for the District of Delaware on Feb. 17, 2009.
Answer, Defenses, and Counterclaims of Mylan, Inc. and Mylan Pharmaceuticals, Inc.,Eurand, Inc., Cephalon, Inc., and Anesta AGv. Mylan Pharmaceuticals, Inc., Mylan, Inc., Barr Pharmaceuticals, Inc. and Barr Laboratories, Inc., Civil Action No. 1:08-cv-00889-SLR, filed with the United States District Court for the District of Delaware on Dec. 16, 2008.
Barr Laboratories, Inc.'s Answer, Affirmative Defenses and Counterclaims,Eurand, Inc., Cephalon, Inc., and Anesta AGv. Mylan Pharmaceuticals, Inc., Mylan, Inc., Barr Pharmaceuticals, Inc. and Barr Laboratories, Inc., Civil Action No. 1:08-cv-00889-SLR, filed with the United States District Court for the District of Delaware on Dec. 16, 2008.
Eurand, Inc. and Anesta AG's Answers to Defendant Barr Laboratories, Inc.'s Counterclaims,Cephalon, Inc., and Anesta AGv. Mylan Pharmaceuticals, Inc., Mylan, Inc., Barr Pharmaceuticals, Inc. and Barr Laboratories, Inc., Civil Action No. 1:08-cv-00889-SLR, filed with the United States District Court for the District of Delaware on Jan. 8, 2009.
Eurand, Inc., Cephalon, Inc., and Anesta AG's Answers and Affirmative Defenses to Mylan Inc. and Mylan Pharmaceuticals, Inc.'s Counterclaims,Cephalon, Inc., and Anesta AGv. Mylan Pharmaceuticals, Inc., Mylan, Inc., Barr Pharmaceuticals, Inc. and Barr Laboratories, Inc., Civil Action No. 1:08-cv-00889-SLR, filed with the United States District Court for the District of Delaware on Jan. 30, 2009.
Eurand, Inc., Cephalon, Inc., and Anesta AG's Notice of Voluntary Dismissal,Eurand, Inc., Cephalon, Inc., and Anesta AGv. Mylan Pharmaceuticals, Inc., and Mylan, Inc., Civil Action No. 1:08-cv-00210-IMK, filed with the United States District Court for the Northern District of West Virginia on Feb. 23, 2009.
First Amended Answer. Defenses, and Counterclaims of Mylan, Inc. and Mylan Pharmaceuticals, Inc.,Eurand, Inc., Cephalon. Inc., and Anesta AGv. Mylan Pharmaceuticals, Inc., Mylan, Inc., Barr Pharmaceuticals, Inc. and Barr Laborato

Affiliated with

Also associated with

Rating

Modified release dosage forms of skeletal muscle relaxants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified release dosage forms of skeletal muscle relaxants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified release dosage forms of skeletal muscle relaxants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4159648